33 results about "Transmembrane peptide" patented technology

The invention relates to anti-viral protein. The anti-viral protein is characterized in that the anti-viral protein is fusion protein and comprises a transmembrane peptide structural domain and a tandem body which is formed through at least two cytosine deaminase structural domains originated from an APOBEC family, a transmembrane peptide structural domain and various cytosine deaminase structural domains. The transmembrane peptide structural domain in the anti-viral protein provided by the invention ensures the anti-viral protein to have the transmembrane capability and to freely shuttle among cells and enters the cells in a non-receptor and non-energy dependent way; the cytosine deaminase structural domains originated from the APOBEC family ensures that the anti-viral protein can effectively inhibit the reproduction of human immunodeficiency virus and / or hepatitis B virus after entering cells; because the non-essential sequences in the APOBEC family protein molecules are removed, not only the antiviral activity of the APOBEC family protein molecules is preserved, but also the immunogenicity of the anti-viral protein is reduced, and the transmembrane efficiency of the anti-viral protein is enhanced.

The disclosure provides fusion proteins containing N-terminal signal peptides fused to immunogenic polypeptides. The immunogenic polypeptides may be from viruses, bacteria, or fungi. The disclosure also provides elevated expression of the immunogenic polypeptides using the N-terminal signal peptide. The N-terminal signal peptides enhance synthesis of the protein, particularly where the protein is neither a secretory nor a transmembrane peptide. The fusion proteins may be used to diagnose disease and to induce immune responses.

The invention discloses a fusion protein TAT (transactivator of transcription)-OCT4 (octamer-binding transcription factor 4), and a coding gene and application thereof. The fusion protein provided by the invention comprises a TAT transmembrane peptide and a cell reprogramming correlation factor combined with an amino end or carboxyl end of the TAT transmembrane peptide. After the fusion protein-TAT OCT4 is used for treating HAFs (human aortic fibroblasts), the proliferation of the fibroblasts is promoted, and the enhancement of the expression level of the cyclins in the fibroblasts is promoted. The TAT transmembrane peptide transported nuclei transcription factor protein can be used as a cell reprogramming method, and can have important application prospects in cell induction and clinic.

The invention provides a preparation method of a fluorescence resonance system for rapid detection of ATP in mitochondria. The method comprises the following steps: step 1, providing a Cy3 fluorescence-labeled ATP-aptamer and an MTS sequence; step 2, performing a coupling reaction for QDs with a complementary strand of the ATP-aptamer and the MTS to obtain QDs molecular probes, wherein QDs is water-soluble quantum dots on carboxyl surface (COOH-QDs) and has a concentration of 1 [mu]M; and step 3, reacting the QDs molecular probes obtained in step 2 with the Cy3 fluorescence-labeled ATP-aptamer to obtain the fluorescence resonance system after interaction of the ATP aptamer and the complementary strand. According to the invention, the method utilizes characteristics of specific binding of the ATP and the aptamer thereof as well as a resonance energy transfer technology, and thus realizes rapid detection of the ATP and also realizes real-time monitoring for changes of ATP concentration in mitochondrial through specific transmembrane peptides-mitochondrial targeting fusion sequence (MTS), thereby providing a novel method for detection and monitoring of the ATP in vitro and in vivo.

The invention belongs to the field of genetically engineered drugs and provides a mutant protein MuR5S4TR of TRAIL, and a preparation method and use thereof. The 2-10th bits of an N-terminal amino acid sequence of the mutant protein are composed of a transmembrane peptide sequence RRRRR (R5) and a binding sequence AVPI of an apoptosis inhibitor XIAP, and the 11-169th bits are TRAIL protein peptide segments (123-281aa). The specific sequence is shown in SEQ ID NO:2.

The invention discloses a transmembrane peptide-mediated antisense antibacterial agent which comprises popliteal lymph node assay (PLNA) 787; and the PLNA 787 is formed by connecting transmembrane peptide (KFF) 3K and LNA 787 by cysteine-(4-(N-maleimide methyl)-1- cyclohexidine actidione)-hexane and is prepared by a solid phase synthesis method. The transmembrane peptide-mediated antisense antibacterial agent takes bacteria curing gene as a target spot, has the advantages of being high in specificity, efficient, low in toxicity, safe and the like, has remarkable inhibition effect on the growth of drug-resistant bacteria, and especially has remarkable antagonism on the growth of methicillin-resistant staphylococcus aureus.

The invention provides a method of handling a hydrophobic agent, which method comprises (a) combining in an aqueous solution (i) a hydrophobic agent and (ii) an isolated peptide that is a structural analog of a transmembrane domain of an integral membrane protein, wherein one terminus of the peptide has one or more negatively charged residues, and (b) allowing the peptide to self-assemble into nanoparticles, wherein the nanoparticles comprise the hydrophobic agent.

The invention relates to gold nanoflower with liver cancer targeting and radiotherapy sensitivity characteristics and a preparation method and application thereof. The gold nanoflower is constructed with a multifunctional responsive surface, so as to realize the liver cancer enrichment and radiotherapy sensitivity characteristics. The gold nanoflower has the advantages that the specific feature and surface plasma resonance properties are realized, so as to facilitate the endocytosis and realize higher X-ray absorbing efficiency; the multifunctional responsive surface is stable under the normalphysiological conditions, so that after the multifunctional responsive surface responds to the microenvironment of tumor, the internal transmembrane peptide molecules are exposed, thereby facilitating the high-efficiency endocytosis of the cells of liver tumor, improving the enrichment degree of the gold nanoflower in the tumor, and prolonging the retention time of the gold nanoflower in the tumor; under the radiation condition by radioactive rays, the better radiotherapy sensitivity effect is realized.

The invention belongs to the technical field of biological engineering, and particularly relates to application of EGFP-CTA2-TAT fusion protein to preparation of a fluorescent probe. A TAT part contained in the structure of the EGFP-CTA2-TAT fusion protein is transmembrane peptide which can help a designed fluorescent probe to run through a cell membrane into the interior of a cell; a CTA2 part contains an endoplasmic reticulum positioning sequence KDEL which can achieve targeted positioning of an endoplasmic reticulum in the cell; the fusion protein can achieve real-time microscopic tracing detection of the endoplasmic reticulum in a living cell and the corresponding physiological change thereof ultimately by exciting EGFP to emit green fluorescence. Compared with an ordinary endoplasmicreticulum staining agent, the fusion protein has the characteristics of good biocompatibility, safety, non-toxicity and higher targeting performance and detection sensitivity.

The invention discloses a targeted cell-penetrating peptide photosensitizer and a preparation method and application thereof. The targeted cell-penetrating peptide photosensitizer has higher targetingability and can be used for interaction of a targeted cell transmembrane peptide of a squamous carcinoma cell cytomembrane and a translocator on the squamous carcinoma cell cytomembrane so that the photosensitizer molecules enter and are gathered in squamous carcinoma cells. The targeted cell-penetrating peptide photosensitizer can activate a PERK-eIF signaling pathway in the squamous carcinoma cell to induce autophagy of tumor cells and can promote squamous carcinoma cell killing through inducing autophagy effects. The targeted cell-penetrating peptide photosensitizer improves molar light absorptivity of the squamous carcinoma cell to a photosensitizer and fully transforms lights into cytotoxic substances. The targeted cell-penetrating peptide photosensitizer satisfies the biological characteristics of the tumor cells and has better targeting effects on squamous carcinoma cells.

The invention relates to a targeted traceless release drug conjugate and a preparation method and application thereof. The invention specifically discloses a targeted traceless release drug conjugate.The targeted traceless release drug conjugate has a structure of T-L-D, wherein T represents a targeting group, L represents a linker and D represents an active ingredient, T is selected from an RGDpeptide, a cyclic RGD peptide, an RGD peptide derivative, an RGD cyclic peptide derivative, folic acid, a transmembrane peptide, a nucleic acid aptamer and a fluorescent dye; D is a pharmaceutical active ingredient with a tertiary amine group, is preferably Coibamide A and a Coibamide A derivative; and L is A-BC-E and BC represents a cleavage site. According to the invention, the cyclic RGD whichhas a targeting effect and is easy to synthesize and modify is used for replacing an antibody which is expensive and difficult to synthesize as the targeting molecule, the preparation is simple, a quite high specific targeting effect is also achieved, and meanwhile, and under the specific cutting effect of enzyme, traceless release of a pharmaceutical active ingredient is realized through self-elimination of aminobenzyl quaternary ammonium salt.

The invention relates to a film-through polypeptide modified virus imitation gene carrier system in the field of biology technology. It adopts nanometer particle which is formed by high molecular material with film-through polypeptide modified kation to prepare for the virus imitation gene carrier system. It uses the mode of admixing the virus imitation surface and the polypeptide modified non-virus carrier and simulating the virus to enters into the cell to improve the gene transmitting effect.

The invention discloses construction of Lactobacillus crispii BT1386 and application in treatment of bacterial vaginosis. First, human and mouse chemokine CXCL12 also known as stromal cell-derived factor-1 (SDF-1) is chemically synthesized, and the human and mouse chemokine CXCL12 belongs to is a small molecule protein in a CXC chemokine family. Secretory expression transmembrane peptide SPusp45 which is unique to Lactococcus lactis is added to construct a recombinant plasmid pMG36e-CXCL12, and the recombinant plasmid is then electrotransformed into the Lactobacillus crispii BT1386 to achievesecretory expression of the chemokine CXCL12. The chemokine CXCL12 is continuously expressed by vaginal embolization to achieve the remission and treatment of the bacterial vaginosis.

Provided are construction of Lactobacillus curvularius ATCC 55221 and application thereof in treatment of parturient nipple rhagadia. First, the human and mouse chemokine CXCL12, also known as stromalcell-derived factor-1 (SDF-1), is a small molecule protein belonging to the CXC chemokine family. The secretory expression transmembrane peptide SPusp45, which is unique to Lactococcus lactis, was added to construct a recombinant plasmid pMG36e-CXCL12, which was then electroporated into the Lactobacillus crispus ATCC 55221 to achieve the secretory expression of the chemokine CXCL12. By external application of nipple wound application, on the one hand, the direct secretion of chemokine CXCL12 can achieve rapid repair of nipple wounds; on the other hand, infants or newborns can obtain probioticsupplements by direct sucking, helping infants Or the newborn balances the intestinal flora to improve autoimmunity.

The invention discloses a ternary gene delivery system based on cell-penetrating peptide and applications of the ternary gene delivery system. The ternary gene delivery system based on the cell-penetrating peptide is prepared by adopting the following method: multifunctional polypeptide REDV-G-TAT-G-NLG-C is connected to eight active sites of octa ammonium POSS (polyhedral oligomeric silsesquioxane) through orthopyridyl disulfide-PEG-NHS ester, and thus a star polymer is formed; the star polymer with positive charges and a gene with negative electricity are bonded through electrostatic interaction, and thus a binary gene delivery system with negative electricity on the surface is formed; a polypeptide sequence rich in histidine and the binary gene delivery system are bonded through electrostatic interaction, and thus the ternary gene delivery system is formed. The ternary gene delivery system based on cell-penetrating peptide provided by the invention has targeting ability for endothelial cells, and has the functions of cell-penetrating peptide, histidine and nuclear localization signals, so that carried genes can efficiently enter cells, the escape from endosome is effectively carried out, the entering of the genes into the cell nucleus is realized, and finally, the gene delivery effect is greatly improved.

Provided is a TRAIL membrane-penetrating peptide-like mutant MuR6, its preparation method and application. The mutant is obtained by selectively transforming the 114th to 119th amino acid coding sequence of the extracellular segment of the TRAIL wild-type protein from VRERGP to RRRRRR, Become a protein containing a penetrating peptide structure. The TRAIL mutants can be used to treat tumors.

The invention belongs to the technical field of gene modification of enzyme preparations, and particularly relates to a preparation method of superoxide dismutase with membrane crossing capability and high stability. The method is characterized by comprising the following steps: extracting mRNA from geobacillus stearothermophilus, synthesizing cDNA by utilizing a reverse transcription means, designing a specific primer to massively amplify coding regions of the cDNA, linking the coding regions to an E.coli expression vector, and then transforming the E.coli expression vector into an engineering bacterium BL21 (DE3). The stability of the superoxide dismutase is enhanced by utilizing a point mutation technology, and a flexible polypeptide connexin GGGSGGGS is designed, so that the soluble fusion expression of the transmembrane peptide YGRKKRRQRRR and the superoxide dismutase is successfully realized. The method has the beneficial effects that the thermal stability of the superoxide dismutase obtained by the method can be improved to the greatest extent; and a CPP sequence YGRKKRRQRRR (i.e., a trans-activating transcriptional activator sequence) with the membrane crossing capability on an HIV-1 peptide fragment and superoxide dismutase are subjected to coupled expression, and the transmembrane performance is given to the superoxide dismutase.

The present invention provides a tandem penetrating peptide modified tumor targeting and tumor penetrating nano drug delivery system that simultaneously recognizes integrin receptors and transmembrane protein receptors. The tandem penetrating peptide is mainly a DGR polypeptide. The fragment is formed by covalently connecting to the C-terminus of the penetrating peptide polyarginine, and the polypeptide can not only selectively recognize receptors highly expressed on the surface of two types of tumor cells, but also efficiently mediate into cells. The nano-drug delivery system is mainly composed of nano-carriers, drugs and lipid-polyethylene glycol-tandem transmembrane peptide ligand chimeras, and is a potential tumor-targeted therapy carrier.

The invention, which relates to the technical field of beautifying products, provides a beautifying and anti-aging composition and application thereof. The separated and extracted karyocyte is rich inTAT protein belonging to cationoid type cell transmembrane peptide and foreign protein, nucleic acid and other substances can be mediated to safely and effectively enter the cell under the conditionof not destroying the cell membrane; the karyocyte is directly conveyed to the subcutaneous part, minimally invasive surfaces can be quantitatively, accurately and finely formed on epidermis, dermis and subcutaneous surfaces in a fixed-point and fixed-layer manner; the minimally invasive surfaces start self-healing and generate collagenous fibers and viscous protein, the collagenous fibers and theviscous protein serve as adhesives between cells, and the karyocyte is combined to activate cell regeneration functions at different levels, so that the effects of wrinkle smoothing, plumping, loosening, tightening and prolapse improvement can be realized. Meanwhile, the subcutaneous thickness can be continuously increased, wrinkles can be smoothened, sunken parts can be accurately filled, and the effect of skin plumpness is realized.

The invention provides a high-flux prey antagonist screening method based on membrane binding protein and fluorescence complementation, relates to the field of gene engineering, and concretely discloses a novel method for screening a receptor antagonist and application thereof. According to the method, a ligand existing outside a cell and a receptor are expressed to the cytomembrane through a signal peptide fusion expression strategy; a ligand structural domain generating mutual action with the receptor is enabled to be remained at the outer side of the cytomembrane; the ligand is coupled with intracellular effect proteins through transmembrane peptide; the ligand and the receptor take mutual effects at the outer side of the cytomembrane, or the effect proteins coupled in the cells are antagonized; and the effect is converted into a macroscopical biological effect, so that the method is provided for the screening of the secretion type ligand and receptor antagonists.

The invention belongs to the technical field of bioengineering, and in particular relates to an EGF-like protein, a construction method thereof, a chimeric protein, a preparation method and application thereof. The invention provides an EGF-like protein, and the EGF-like protein is EGF‑CTA 2 ‑TAT protein, EGF‑CTA 2 The nucleotide sequence of the -TAT protein is shown in SEQ ID NO:1. EGF-CTA of the present invention 2 ‑TAT protein is chimerized with EGF protein with repair function, membrane-penetrating peptide TAT to assist transdermal absorption, and cholera toxin A2 subunit (CTA) with the ability to penetrate the cell membrane 2 ), the cell activity test results showed that EGF‑CTA 2 ‑TAT protein has obvious growth-promoting effect on BALB / c 3T3 cell line and has biological activity.

The invention provides a method of handling a hydrophobic agent, which method comprises (a) combining in an aqueous solution (i) a hydrophobic agent and (ii) an isolated peptide that is a structural analog of a transmembrane domain of an integral membrane protein, wherein one terminus of the peptide has one or more negatively charged residues, and (b) allowing the peptide to self-assemble into nanoparticles, wherein the nanoparticles comprise the hydrophobic agent.

The invention discloses a preparation method of an RGD peptide and penetrating peptide R8 co-modified ergosterol and cis-platinum active drug-loading liposome. The method comprises the main steps of ergosterol liposome preparation, ammonium chloride gradient formation, drug loading and co-modification. The method is simple in technology and easy to carry out, and the encapsulation rate of a drug is high; ergosterol is adopted to partially replace cis-platinum to exert efficacy, an ergosterol and cis-platinum active drug-loading liposome is obtained, the effect of resisting a lung cancer is guaranteed, the toxic and side effects of the drug are significantly reduced, and damage to human bodies is small; meanwhile, the RGD peptide and the penetrating peptide R8 serve as target heads, the targeting property is good, and the drug exertion effect is good.

The present invention belongs to the field of genetic engineering drugs, and provides a mutein MuR5S4TR of TRAIL, and a preparation method and use thereof. The N-terminal positions 2-10 of the amino acid sequence of the mutein consist of the transmembrane peptide sequence RRRRR (R5) and the binding sequence AVPI of the apoptosis inhibitor XIAP, the positions 11-169 are the TRAIL protein peptide segment (123-281 aa), and the specific sequence is as shown in SEQ ID NO: 2.

The invention relates to anti-viral protein. The anti-viral protein is characterized in that the anti-viral protein is fusion protein and comprises a transmembrane peptide structural domain and a tandem body which is formed through at least two cytosine deaminase structural domains originated from an APOBEC family, a transmembrane peptide structural domain and various cytosine deaminase structural domains. The transmembrane peptide structural domain in the anti-viral protein provided by the invention ensures the anti-viral protein to have the transmembrane capability and to freely shuttle among cells and enters the cells in a non-receptor and non-energy dependent way; the cytosine deaminase structural domains originated from the APOBEC family ensures that the anti-viral protein can effectively inhibit the reproduction of human immunodeficiency virus and / or hepatitis B virus after entering cells; because the non-essential sequences in the APOBEC family protein molecules are removed, not only the antiviral activity of the APOBEC family protein molecules is preserved, but also the immunogenicity of the anti-viral protein is reduced, and the transmembrane efficiency of the anti-viralprotein is enhanced.

The invention discloses a transmembrane peptide-mediated antisense antibacterial agent which comprises popliteal lymph node assay (PLNA) 787; and the PLNA 787 is formed by connecting transmembrane peptide (KFF) 3K and LNA 787 by cysteine-(4-(N-maleimide methyl)-1- cyclohexidine actidione)-hexane and is prepared by a solid phase synthesis method. The transmembrane peptide-mediated antisense antibacterial agent takes bacteria curing gene as a target spot, has the advantages of being high in specificity, efficient, low in toxicity, safe and the like, has remarkable inhibition effect on the growth of drug-resistant bacteria, and especially has remarkable antagonism on the growth of methicillin-resistant staphylococcus aureus.

The invention relates to a preparation method of anti-human seminoprotein specific single-chain antibody and an application method, wherein the preparation method comprises that the inducer has histidine tail and transmembrane peptide threonine-alanine-threonine at the terminal of amido, the ascending inducer is 5'-CGCTTAATTAAA AAG CAG ACC GCG ACC CAT ATG ACC CAG GTC CAA CTG CAG-3', the descending inducer is 5'-TTAGTTAGTTACCGGATCCC ACG TTT GAT CTC CAG-3', the total length is 783bp, using polymerase chain reaction to obtain anti-human gamma-seminoprotein single-chain antibody gene segment, using the gene segment as template to prepare anti-human gamma-seminoprotein single-chain antibody. The antibody can be used to build variable prostate cancer antigen serology detection kit and can be connected with nanometer particles as magnetic nanometer particle and quantum dot to prepare the magnetic nanometer particle and quantum dot covered by gamma-seminoprotein single-chain antibody.

The invention relates to the field of biomedicine, particularly to a fusion protein. The fusion peptide comprises a first peptide fragment region and a second peptide fragment region, the C terminal of the first peptide fragment region is connected to the N terminal of the second peptide fragment region, wherein the first peptide fragment region includes a secretion signal peptide, and a phosphatidylserine binding protein peptide segment, the second peptide fragment region includes a connecting peptide segment and a transmembrane peptide segment, the phosphatidylserine binding protein peptide segment includes an phosphatidylserine antibody or a peptide segment in specific bonding with phosphatidylserine in annexin. The fusion protein provided by the invention has the characteristics of cell membrane protein and the ability of combining with a lipid bilayer structure, cytokine induced killers or stem cells expressing the protein can have the ability of tissue infiltration or enrichment at disease tissues and injured parts, and the fusion protein can be used for tracer, imaging, chemotherapy or phototherapy of disease tissues.

The disclosure provides fusion proteins containing N-terminal signal peptides fused to immunogenic polypeptides. The immunogenic polypeptides may be from viruses, bacteria, or fungi. The disclosure also provides elevated expression of the immunogenic polypeptides using the N-terminal signal peptide. The N-terminal signal peptides enhance synthesis of the protein, particularly where the protein is neither a secretory nor a transmembrane peptide. The fusion proteins may be used to diagnose disease and to induce immune responses.